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Abstract
For decades, chemokines and their receptors have received a great deal of attention for their multiple roles in
controlling leukocyte functions during inflammation and immunity. The ability of chemokines to convey remarkably
versatile but context-specific signals identifies them as powerful modulators of immune responses generated in
response to diverse pathogenic or non-infectious insults. A number of recent studies have speculated that the C-C
chemokine receptor type 7 (CCR7), plays important roles in immune-cell trafficking in various tissue compartments
during inflammation and in immune surveillance. Using computational modeling and microfluidics-based
approaches, recent studies have explored leukocyte migration behavior in response to CCR7 ligands in a complex
chemokine environment existing with other coexisting chemokine fields. In this review, we summarize the current
understanding of the effects of soluble versus immobilized ligands and of the downstream signaling pathways of
CCR7 that control leukocyte motility, directionality, and speed. This review also integrates the current knowledge
about the role of CCR7 in coordinating immune responses between secondary lymphoid organs and peripheral
tissue microenvironments during primary or secondary antigen encounters. CCR7 seems to influence distinct
immunological events during inflammatory responses in the central nervous system (CNS) including immune-cell
entry and migration, and neuroglial interactions. The clinical and pathological outcome may vary depending on its
contribution in the inflamed CNS microenvironment. Understanding these mechanisms has direct implications for
therapeutic developments favoring more protective and efficient immune responses.
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Background
CCR7 is a G-protein-coupled receptor that is expressed
mainly on semi-mature and mature dendritic cells (DCs),
naive B and T cells and central memory T cells [1-5]. The
CCR7 ligands, CCL19 and CCL21, are constitutively
expressed on the high endothelial vessels (HEVs) of the
lymph nodes (LNs) and by fibroblastic reticular cells and
follicular dendritic cells forming the conduits that guide
T-cell migration in the LN [6,7]. Hence, CCR7 is the prin-
cipal chemokine receptor that controls DC–T-cell anti-
gen-specific interactions facilitating optimal priming in
the LN [2,8-10]. In addition to its role in development and
maintenance of secondary lymphoid organs, CCR7 signal-
ing is involved in a number of immunological processes
such as the generation of thymocytes [11,12], central and
peripheral tolerance [13,14], regulatory T-cell (Treg) func-
tion [15-17] and T-cell homeostasis [18] (Table 1).
In recent years, considerable effort has been devoted to
understanding the mechanisms of how CCR7 signaling
components control leukocyte propulsion and directional
migration [37-40]. These mechanisms have identified CCR7
ligands as potent regulators of leukocyte interactions in
lymphoid tissues and peripheral tissues including the CNS.
In this review, we focus on these properties of CCR7/
CCL21 signaling and its role in generating protective im-
mune responses, particularly those occurring in the CNS.
Signaling properties of CCR7 and its ligands
CCR7 is a seven trans-membrane domain receptor protein
coupled with pertussis toxin-sensitive Gai components.
Signaling of immobilized CCR7 ligands through their re-
ceptor causes lymphocytes to go from a ‘rolling’ state to
an ‘arrest’ state on endothelial surfaces, and subsequent
activation and redistribution of integrin molecules leads to
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lymphocyte transendothelial migration [2,41]. CCR7 sig-
naling components have multiple features that allow them
to govern a wide range of leukocyte functions in different
tissue microenvironments. An important aspect of the
CCR7 chemokine system is its transcriptional regulation.
Although CCR7 has been established as a homeostatic
chemokine receptor, both CCR7 and its ligands are also
inducible during inflammation to coordinate complex
leukocyte trafficking between the peripheral versus the
lymphoid tissue [24,42,43]. Importantly, ligation of CCL19
versus CCL21 may allow CCR7 to exert differential effects
within tissue for the following reasons.
1) CCL21 has an affinity more than 10-fold higher than
CCL19 for binding collagen and other extracellular
molecules, thus allowing it to be a better candidate
to form an immobilized chemokine gradient [44].
2) CCL19 and CCL21 are natural biased ligands of CCR7,
which have equivalent efficacy for G-protein activation
but possess differential engagement of the G-protein-
coupled receptor kinase (GRK)/β-arrestin system [45]
and hence presumably differentially phosphorylate
CCR7 [46] (Figure 1). Thus, CCL19 but not CCL21
binding to CCR7 induces receptor desensitization and
clathrin-mediated internalization [47-49]. This may
result in local changes in the chemokine environment
that would optimize directed immune responses.
3) Differential expression and localization of CCL19
and CCL21 in different regions of the tissue have a
functional significance that can influence the
position of lymphocytes and DCs in the LN and
spleen tissue microenvironment [25,39].
4) CCL21 and CCL19 are the only ligands for CCR7.
However, CCL21 can also signal through CXCR3, a
prominent inflammatory chemokine receptor in Th1
immune responses [50,51].
5) CCR7 ligands share only 32% sequence homology.
CCL19 is an obligate soluble ligand, whereas CCL21
remains membrane-bound because of the presence of
a glycosaminoglycan binding domain [37,52-54].
These soluble and immobilized ligands therefore have
the potential to induce different functional responses
even though they signal through the same receptor.
CCR7 downstream signaling uses multiple independent
modules to control distinct leukocyte functions (Figure 1).
In DCs, chemotaxis toward CCR7 ligands involves G-
inhibitory-mediated activation of mitogen-activated pro-
tein kinase family members, and their migratory speed is
controlled by Rho–coffilin phosphorylation [55,56]. Thus,
actin and myosin inhibitors affect only the speed of crawl-
ing, whereas pertussis toxin inhibits the directed motion
of bone-marrow-derived DCs [38].
Recently, significant conceptual advances have been
made, based on ex vivo and in vitro experimental models
investigating how soluble versus immobilized CCR7
ligands influence the speed, motion, and directionality of
leukocyte movement within lymphoid tissues [37,39,40].
Table 1 Summary of roles of CCR7
Role in the immune system Mechanism References
Thymic architecture
and function
CCR7 is involved in the recruitment of fetal hematopoietic progenitors
and coordination of migratory events of thymocytes at their different




CCR7 is required for Treg cell homing and positioning within
the paracortical LN area. Treg function is impaired in
CCR7-deficient mice
[15-17]
T-cell priming Age-experienced DCs (entering via afferent lymphatics) and
T cells (via HEVs) use CCL21-coated stromal networks in the T-cell





CCR7 and CCL21 contribute to T-cell recruitment and egress from





Tolerogenic (homeostatic) DCs and inflammation-induced DCs
acquire CCR7 expression as they exit from peripheral tissues to





CCR7-mediated signaling positively regulates the survival and
rate of endocytosis of the mature DCs. CCR7 also induces dendritic
cytoplasmic extensions that may contribute to the ability of DCs to
present antigens
[31-33]
T-cell homeostasis CCR7 ligands support the survival and homeostatic
expansion of naive T cells
[18,34]
B-cell help CCR7 upregulation mobilizes follicular B cells towards the
T-cell zone in the LN to receive ‘help’ from CD4+ T helper cells
[35,36]
CCR7 C-C chemokine receptor 7; DC dendritic cell; HEV high endothelial vessel; LN LN.
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Studies conducted using two-dimensional microfluidic
devices have shown that CCL19 is apparently 100-fold
more potent than CCL21 for DC chemotaxis [38], and is
also a more potent chemoattractant than CXCL12 for
activated T cells [57]. By contrast, another recent study
used microfluidics-based approaches to generate chemo-
kine gradients on three-dimensional (3D) matrices mimick-
ing the 3D tissue environment in vivo [40]. This latter
study found that when CCL21 and CCL19 are presented
on competing overlapping gradients, DC migration will fol-
low CCL21. A similar preference is seen in human periph-
eral blood T cells that are chemotactic to CCL21 but not
CCL19 under physiological gradient conditions [39]. The
differential ability of CCL19 and CCL21 to desensitize the
receptor may fine-tune the intensity of CCR7 signaling
in coexisting chemokine fields, potentially explaining the
preferential migration to CCL21. Furthermore, DCs prefer-
entially chemotax towards CCL21 even if not bound to the
tissue matrix [40]. In support of these data, using a 3D gel
carbon-fiber system, Schumann et al. found that the
adhesive random migration of DCs is mediated through
immobilized CCL21, but, the directional cues come from a
soluble form of CCL21 generated from protease cleavage
by the migrating DCs [37]. Although the authors showed
the existence of a truncated form of CCL21, the question
remains whether this soluble form is produced homoge-
nously or as a gradient in vivo, and if the latter, how
this gradient is formed in a manner that favors migration
towards the T-cell zone. In addition, it has not yet been
explained how this model fits with the T-cell entry and exit
strategy from the LNs. However, data from these studies
indicate that leukocyte migration behavior to a specific
chemoattractant may vary depending on other coexisting
chemokine fields, their physiological gradient strength, state
of the ligand (soluble versus bound), and tissue-matrix
components [37-40,57].
Role of CCR7 in protective immunity
The role of CCR7 and its ligands in leukocyte guidance is
most evident during T cell entry into the LN via HEVs and
DC entry through the afferent lymph vessels [2,6,58,59]. Im-
mature DCs continuously sample the antigen milieu in the
Figure 1 Differential consequences of CCL19 versus CCL21 ligation to C-C chemokine receptor 7. CCR7 signaling activates the mitogen-
activated protein kinase signaling module leading to chemotaxis, whereas the Rho-coffilin signaling axis is involved in controlling the migratory
speed of leukocytes. Ligand binding to and activation of CCR7 leads to its phosphorylation by GRKs that recruit β-arrestin scaffold proteins.
Signaling by both CCL19 and CCL21 causes GRK6 to phosphorylate CCR7. In addition, GRK3 phosphorylates CCR7 after CCL19 ligation only. The
differential phosphorylation pattern may recruit distinct functional pools of β-arrestins that leads to the differential ability of CCR7 ligands to
induce clathrin-dependent receptor endocytosis and desensitization. After internalization, CCR7 recycles back to the plasma membrane, whereas
CCL19 is sorted to lysosomes for degradation.
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tissue. When they sense danger signals, they exit as CCR7
+ mature DCs via the afferent lymphatics to present anti-
gen in the lymphoid tissues [60,61]. In addition, CCL21-
coated stromal networks allow antigen-experienced DCs
to establish physical contact with T cells [6,58,59]. CCR7
also appears to be crucial for DC migration from other
peripheral tissues such as gut and lung to their corre-
sponding draining LNs [29,30]. These steady state DCs
have recently been shown to contribute to T-cell homeo-
stasis by producing vascular endothelial growth factor
[62], thus they are able to support HEV formation and
may facilitate T-cell entry into the LNs [62]. Such steady
state DCs further influence T-cell populations within the
LN by increasing CCL21 expression on fibroblastic reticu-
lar cells and by their ability to bind free CCL21 [62]. This
binding ability is CCR7- independent, but will result in
the retention of CCL21 in LNs [62]. Whether or not sig-
naling or behavior of antigen-dependent interactions
between DCs and T cells is affected when the DC is also
‘presenting chemokine’ remains to be investigated.
CCR7-deficient or plt/plt mice (lacking CCL19 and
CCL21-Ser within secondary lymphoid organs) display
gross alterations in the micro-architecture of spleen and
thymus, and their DCs and T cells fail to home to the
spleen and LN T-cell zones [2,59,63]. Consequently,
CCR7-deficient mice display delayed and impaired adap-
tive immune responses, especially in the absence of large
amounts of antigen [2,35]. Because antigen presentation
at ectopic sites might also activate T cells and produce im-
munity, the requirement of CCR7 for protective immune
responses may vary depending on the pathogen. Although
CCR7-deficient mice displayed reduced T-cell priming
after infection with lymphocytic choriomeningitis virus or
Listeria monocytogenes, mice were able to generate suffi-
cient immune responses [64,65]. On the single cell level,
CCR7−/− CD8+ T cells gained normal effector function,
Figure 2 Models proposing the role of CCL21 during inflammation in the brain. (a) CCL19 and CCL21 expression at the blood–brain barrier
(BBB) may aid extravasation of CCR7+ leukocytes. During pathogenic insults, CNS-resident glial cells induce CCL21 which in turn facilitates T-cell
migration from the perivascular area to the site of infection to keep pathogens under control; (b) Ischemia- or glutamate-mediated damage
causes neurons to release CCL21 from the primary lesion site to activate microglia through the CXCR3 receptor. CXCR3-CCL21 signaling-mediated
neuroglial communication is a potent mechanism to activate glial cells that are present at a distant site from the lesion.
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and antiviral protection was complete but delayed in
CCR7-deficient mice [64]. Unlike CCR7−/− mice, plt/plt
mice were able to mount unimpaired antiviral CTL
responses, probably due to the expression of another iso-
form of CCL21 (CCL21-leu) in lymph vessels and periph-
eral tissues [66]. However, during the acute phase of
infection with the protozoan parasite, Toxoplasma gondii,
CCR7 appeared to be an absolute requirement for the
generation of protective immune responses, despite the
systemic nature of this infection and the presence of abun-
dant antigen [43]. This was associated not only with
delayed T-cell responses including decreased interferon-γ
production, but also a significant defect in the recruitment
of inflammatory macrophages [43]. This points to either a
direct or indirect role for CCR7 interactions in the recruit-
ment of cells from the bone marrow.
Circulation of T cells between peripheral tissues and
lymphoid organs is essential for immune surveillance and
host defense of non-lymphoid sites. Upon stimulation by
their cognate antigen, naive T cells become activated and
change their chemokine receptor expression profile to mi-
grate out of the LN via the efferent lymph [67]. Therefore,
inflammation results in a large influx of lymphocytes into
peripheral tissues from the bloodstream. Like few other
chemokine receptors, CCR7 has been suggested to be a
key regulator of lymphocyte migration from blood to spe-
cific peripheral tissues [68,69]. Upregulation of CCR7 and/
or its ligands has been previously shown in inflamed tis-
sues such as liver, lung, kidney, and muscle [26,70-72]
contributing to lymphocyte recruitment and the gener-
ation of lymphoid-like structures [25,26].
In a number of studies, CCR7 deficiency led to abnor-
mal lymphocyte accumulation in peripheral tissues such
as skin and lung, in which CCR7 is apparently not con-
trolling the entry of activated lymphocytes [24,27]. These
observations led to the idea that lymphocytes may also
need CCR7 to egress from the body cavities and extra-
lymphoid tissue compartments via the afferent lymph.
CCR7 deficiency led to massive accumulation of both
CD4+ and CD8+ lymphocytes in the pleural and peri-
toneal cavities [28]. CCR7 expression is also required for
T-cell migration from skin, although CD4+ and CD8+
lymphocytes show differential requirements [27]. CCR7
determines the tissue exit of antigen-specific T cells, and
also guides their entry into the mediastinal LN via the
afferent lymph of asthmatic lung tissue [24]. DCs resid-
ing in tissue surfaces exposed to the external environ-
ment such as those in the gut, airway, and skin also use
CCR7 to migrate out of the tissues towards peripheral
LNs [3,29,30]. Recently, two-photon microscopy used to
monitor intralymphatic microinjection demonstrated
that CCR7 is dispensable for the parenchymal entry of
lymph-derived T cells [73]. However, CCR7 is absolutely
required for the directional migration of both DCs and
T cells into the T-cell zone in LNs [73]. To summarize,
CCR7 orchestrates leukocyte navigation between lymph-
oid organs and inflamed sites in order to ensure an effi-
cient adaptive immune response.
CCR7 in central nervous system-specific immune
responses
CNS immunity requires the production of appropriate
immune responses that are robust enough to control
pathogens but at the same time contained to prevent
damage in an area in which inflammation is physically
restrained by the skull and is dense with sensitive neu-
rons not normally replaced in adult life [74-77]. For
decades, the CNS has been considered as an ‘immune-
specialized site’ with unique strategies to control the in-
flux of peripheral leukocytes in the brain. Several studies
have suggested CCR7 as a potent chemokine signal to
control CNS entry and migration of lymphocytes in both
healthy and diseased states [42,78-80].
During homeostasis, peripheral immune cells continu-
ously survey for ongoing infection or tissue damage in
the brain; however, their migration is restricted. The
major route for immune-cell entry and antigen sampling
is via the choroid plexus and the meningeal veins into
the subarachnoid space [77]. The secretory epithelium of
the choroid plexus produces cerebrospinal fluid (CSF)
that circulates through the ventricles of the brain. Con-
stitutive expression of CCL19 has been found in the CSF
[79], and therefore it is proposed that, after integrin-
dependent adhesion, CCR7 signaling may mediate further
activation and slowing of lymphocytes on the endothelium
to facilitate transendothelial migration [81].
Infection in the periphery leads to the development of
a stable, antigen-independent CCR7+ central memory T-
cell population with the potential to modulate the qual-
ity of T-cell responses after secondary antigen encounter
[82,83]. Recent studies on the cellular composition of
CSF indicate that most lymphocytes in the CSF express
a central memory phenotype with high levels of CCR7
and L-selectin [84,85]. These data, along with evidence
of the presence of CCL19 in the CSF of healthy indivi-
duals suggest that perhaps as part of routine surveil-
lance, CCR7–CCL19 interactions regulate the entry of
central memory T cells into the subarachnoid space [79].
When these cells recognize their cognate antigen, they
switch to an effector/activated phenotype, and hence
gain access to the CNS parenchyma [86].
In response to inflammatory insults, activated CNS-
resident cells induce the expression of adhesion mole-
cules and chemokines that allow circulating leukocytes
to bind and extravasate from the cerebral vasculature
into the CNS parenchyma [77,87,88]. In experimental
autoimmune encephalomyelitis (EAE), an animal model
of multiple sclerosis (MS), encephalitogenic T cells
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extravasate from post-capillary CNS venules [78,81].
Functional expression of CCL19 and CCL21 has been
reported in these inflamed CNS venules [78,89]. Block-
ing of CCR7 signaling reduced binding of T cells to
inflamed venules of EAE brain sections [78,81]. In
addition, during EAE, CCR7+ cells accumulated in peri-
vascular cuffs and meningeal infiltrates of the brain [89],
a finding corroborated further in patients with MS in
whom CSF has been found to be enriched with CCR7+
T cells and DCs. By contrast, T cells in MS lesions do
not express CCR7, an indication that downregulation of
CCR7 after blood–brain barrier transmigration may
occur [86]. Similarly, CCL19 transcripts have been found
to be upregulated in active and inactive MS specimens
[79]. In patients with relapsing-remitting or secondary
progressive MS, CCL19 transcript levels correlated with
intrathecal IgG production [79]. These data suggest that
CCL19 may be involved in B-cell trafficking and expansion
in the inflamed CNS. Thus, CCR7 is a potential candidate
along with other current B-cell-selective therapeutic
approaches to reduce humoral responses in patients with
MS [90,91].
Independent of its role in T cell migration, CCR7 signal-
ing has been implicated in the differentiation of T cells
[92]. During allergic rhinitis, the absence of CCR7 ligands
results in aberrant T helper (Th)2 responses caused by a
reduction of Tregs in the cervical LNs (cLN) [93]. By con-
trast, CCR7 signaling has been found to stimulate DCs to
produce IL-23 and IL-12 and to generate Th17 and Th1
cells [92]. Thus, deficiency of CCR7 ligands was found to
be protective against development of EAE caused by a de-
fect in IL-23 dependent induction of Th17 cells [92].
Therefore the role of CCR7 in polarizing the immune re-
sponse is context-specific and may act more as a co-stimu-
latory signal, as previously reported for CCR5 and CXCR4
[94].
Expression of CCL21 alone is sufficient to recruit lym-
phocytes and trigger the formation of ectopic lymphoid
structures in non-immune-privileged sites [95]. Thus,
CCR7 ligands have been thought to contribute to the devel-
opment of follicle-like structures seen in the meningeal
sites of patients with MS [96]. However, transgenic and bio-
available expression of CCL21 in the CNS is not in itself
sufficient to promote lymphocyte recruitment or lymphoid
neogenesis in the healthy CNS [80,97]. Despite massive
lymphocyte infiltration during chronic inflammation, trans-
genic expression of CCL21 did not form lymphoid-like
structures in the CNS parenchyma [80]. Thus, there is no
essential link between CCL19/CCL21 expression and ec-
topic lymphoid tissue formation in the CNS or during MS.
In recent studies, CCR7 has emerged as a potent regu-
lator of neuroimmune crosstalk during inflammation in
the brain. CNS-resident glial cells induce CCR7 ligands
in response to inflammatory insults in the brain [98].
Although few reports have suggested CCR7 expression
by glial cells [98,99], the predominant cell types expres-
sing CCR7 in the CNS are infiltrating CCR7high
lymphocytes and dendritic cells [85,86]. In models of in-
fection-induced inflammation, CCR7 and its ligands
have been clearly shown to play a protective role. Ad-
ministration of CCL21/CCL19 restored T cell dysfunc-
tion seen in lymphotoxin-α/- mice during viral infection,
and increased their resistance to encephalitis [100]. In
addition, profound changes in the expression of CCR7
and its ligands have been detected in the CNS during
the chronic phase of T. gondii infection [42,43]. CCL21
induction appeared as fibrous strands associated with
migrating T cells [42]. This may suggest that upregula-
tion of CCL21 can act as a migratory network within the
brain parenchyma (Figure 2a) [42]. Indeed, CD4+ T-cell
migration in the chronically infected brain parenchyma
is CCL21-dependent, and infection is not controlled in
the absence of CCL21 [80]. Thus, CCL21 upregulation
has been suggested to contribute to CNS protective im-
munity via: 1) homeostatic priming of CD4+T lympho-
cytes outside the CNS and 2) facilitation of CD4+T cell
migration into parenchymal sites within the CNS after
pathogenic insults [80].
CCL21 has also been implicated in glial activation in
non-infectious CNS insults [50,101]. However, several
findings in these models contrast with what has been
established from models of autoimmune responses or
situations in which ongoing inflammation is present due
to CNS infection. Firstly, CNS infection or autoimmune
models report expression of CCR7 ligands on glial cells,
brain endothelial cells or choroid plexus epithelium
[79,86]. By contrast, in both cerebrovascular ischemia
and glutamate-mediated damage, neurons are the source
of CCL21 production [101,102]. Supporting this finding,
endangered cortical and hippocampal neurons have been
shown to release CCL21 in vitro [101]. However, no
CCL21 mRNA was detected from cultured astrocytes or
microglia [102,103]. Secondly, although neuronal release
of CCL21 leads to microglial activation, this is not via
CCR7 but rather another low-affinity receptor, CXCR3
[50,102,104]. In other models of neurological damage
such as during peripheral nerve or spinal cord injury,
CCL21 is released by damaged neurons [105,106]. This
stress-induced CCL21 can be transported as secretory
vesicles along neuronal processes and be released at dis-
tant sites from the source of injury [101]. This
phenomenon indicates a direct mechanism by which
damaged neurons communicate and remotely activate
microglia or other CCL21-responsive cells (Figure 2b)
[105,106]. Thus, CCL21-mediated signaling contributes
during neuronal–immune-glial cell interactions, and is
required to mount appropriate immune responses dur-
ing both infectious and non-infectious insults.
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Conclusion
CCR7 has both soluble and immobilized signaling compo-
nents that are able to exist in a gradient or uniform manner.
Its pleiotropic roles in guiding leukocyte migration make it a
powerful chemokine system for protective immunity during
homeostasis and disease states. The CNS has been consid-
ered as an immune-privileged site because of the presence
of the blood–brain barrier and the absence of a draining
lymphatic system limiting the sampling of antigens present
in the brain. However, more recent data have shown that
the CNS is not immune isolated; rather, it has intrinsic and
extrinsic components that modulate immune responses to
maximize their efficiency. Previously known for its crucial
role as a homeostatic chemokine in lymphoid organs,
CCR7–CCL21 interactions are key to regulating immune
responses at and within the CNS tissue. CCR7- dependent
migration of leukocytes may play a role in pathogen dissem-
ination in specialized peripheral tissues such as the brain.
Thus, careful dissection of the roles of CCR7 signaling in
different models of CNS immune responses will be useful in
understanding leukocyte trafficking during autoimmune
responses or infection.
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